Vi-CRM197 vaccine + Pneumococcal conjugate vaccine + Vi Polysaccharide (PS) vaccine
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Typhoid Fever
Conditions
Typhoid Fever
Trial Timeline
Oct 1, 2011 → Aug 1, 2012
NCT ID
NCT01437267About Vi-CRM197 vaccine + Pneumococcal conjugate vaccine + Vi Polysaccharide (PS) vaccine
Vi-CRM197 vaccine + Pneumococcal conjugate vaccine + Vi Polysaccharide (PS) vaccine is a phase 2 stage product being developed by Novartis for Typhoid Fever. The current trial status is completed. This product is registered under clinical trial identifier NCT01437267. Target conditions include Typhoid Fever.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01437267 | Phase 2 | Completed |
Competing Products
7 competing products in Typhoid Fever
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Purified Vi capsular polysaccharide of Salmonella typhi conjugated to tetanus toxoid as carrier protein (Typhoid Vi Conjugate Vaccine I.P.). Trade name: ZyVac® TCV | Zydus Lifesciences | Phase 3 | 77 |
| Vi-CRM197 vaccine + Vi Polysaccharide (PS) vaccine + Pneumococcal conjugate vaccine | Novartis | Phase 2 | 52 |
| NVGH Vi-CRM197 12.5 mcg + NVGH Vi-CRM197 5.0 mcg + NVGH Vi-CRM197 1.25 mcg + Vi-polysaccharide vaccine | Novartis | Phase 2 | 52 |
| Typherix + NVGH Vi-CRM197 | Novartis | Phase 1 | 33 |
| NVGH Vi-CRM197 | Novartis | Phase 2 | 52 |
| Vivotif | Bavarian Nordic | Pre-clinical | 20 |
| Dose of 5.0 x 10^9 CFU (Cohort 1) + Dose of 7.5 x 10^9 CFU (Cohort 2) + Dose of 1.1 x 10^10 CFU (Cohort 3) + Dose of of 1.7 x 10^10 CFU (Cohort 4) | Emergent BioSolutions | Phase 2 | 44 |